| Literature DB >> 31155496 |
Cristina Aguayo-Mazzucato1, Joshua Andle2, Terrence B Lee2, Ayush Midha2, Lindsay Talemal2, Vaja Chipashvili2, Jennifer Hollister-Lock2, Jan van Deursen3, Gordon Weir2, Susan Bonner-Weir2.
Abstract
Type 2 diabetes (T2D) is an age-related disease. Although changes in function and proliferation of aged β cells resemble those preceding the development of diabetes, the contribution of β cell aging and senescence remains unclear. We generated a β cell senescence signature and found that insulin resistance accelerates β cell senescence leading to loss of function and cellular identity and worsening metabolic profile. Senolysis (removal of senescent cells), using either a transgenic INK-ATTAC model or oral ABT263, improved glucose metabolism and β cell function while decreasing expression of markers of aging, senescence, and senescence-associated secretory profile (SASP). Beneficial effects of senolysis were observed in an aging model as well as with insulin resistance induced both pharmacologically (S961) and physiologically (high-fat diet). Human senescent β cells also responded to senolysis, establishing the foundation for translation. These novel findings lay the framework to pursue senolysis of β cells as a preventive and alleviating strategy for T2D.Entities:
Keywords: SASP; beta cells; glucose metabolism; insulin resistance; insulin secretion; senescence; senescence signature; senescence-associated secretory profile; senolytic therapies; type 2 diabetes
Year: 2019 PMID: 31155496 PMCID: PMC6610720 DOI: 10.1016/j.cmet.2019.05.006
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287